{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:42:18Z","timestamp":1785307338459,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CIN 13-413"],"award-info":[{"award-number":["CIN 13-413"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CX001430"],"award-info":[{"award-number":["CX001430"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 CA206476"],"award-info":[{"award-number":["1R01 CA206476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA174647"],"award-info":[{"award-number":["T32 CA174647"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AIDS Malignancy Consortium","award":["2U01CA121947-04"],"award-info":[{"award-number":["2U01CA121947-04"]}]},{"name":"AIDS Malignancy Consortium","award":["P30 CA125123"],"award-info":[{"award-number":["P30 CA125123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oncogenic viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), Epstein Barr virus (EBV), and Kaposi Sarcoma Herpes virus (KSHV) contribute to a significant proportion of the world\u2019s cancers. Given the sizeable burden of virus mediated cancers, development of strategies to prevent and\/or treat these cancers is critical. While large population studies suggest that treatment with hydroxymethylglutaryl-CoA reductase inhibitors, commonly known as statins, may reduce the risk of many cancer types including HBV\/HCV related hepatocellular carcinoma, few studies have specifically evaluated the impact of statin use in populations at risk for other types of virus mediated cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Studies of populations with HBV and HCV suggest a protective, dose-dependent effect of statins on hepatocellular carcinoma risk and support the theory that statins may offer clinical benefit if used as chemoprophylactic agents to reduce liver cancer incidence. However, no population level data exists describing the impact of statins on populations with other oncogenic viral infections, such as HPV, EBV, and KSHV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Further study of statin use in diverse, global populations with or at high risk for oncogenic viral infections is essential to determine the impact of statin therapy on virus mediated cancer risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13027-022-00460-0","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T07:02:34Z","timestamp":1662274954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Can statins lessen the burden of virus mediated cancers?"],"prefix":"10.1186","volume":"17","author":[{"given":"Eva H.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Chiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"issue":"2","key":"460_CR1","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180\u201390.","journal-title":"Lancet Glob Health"},{"issue":"9","key":"460_CR2","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609\u201316.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"460_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/QAD.0000000000001112","volume":"30","author":"LS Park","year":"2016","unstructured":"Park LS, Tate JP, Sigel K, Rimland D, Crothers K, Gibert C, et al. Time trends in cancer incidence in persons living with HIV\/AIDS in the antiretroviral therapy era: 1997\u20132012. AIDS. 2016;30(11):1795\u2013806.","journal-title":"AIDS"},{"issue":"11","key":"460_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","volume":"16","author":"NA Krump","year":"2018","unstructured":"Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. Nat Rev Microbiol. 2018;16(11):684\u201398.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"460_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","volume":"15","author":"EA Mesri","year":"2014","unstructured":"Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15(3):266\u201382.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"460_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cr.2016.153","volume":"27","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59\u201373.","journal-title":"Cell Res"},{"issue":"1","key":"460_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2009.06.001","volume":"392","author":"HH Zur","year":"2009","unstructured":"Zur HH. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1\u201310.","journal-title":"Virology"},{"issue":"11","key":"460_CR8","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","volume":"33","author":"A Endo","year":"1992","unstructured":"Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569\u201382.","journal-title":"J Lipid Res"},{"issue":"10","key":"460_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1161\/STROKEAHA.114.005832","volume":"45","author":"P Amarenco","year":"2014","unstructured":"Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014;45(10):2974\u201382.","journal-title":"Stroke"},{"issue":"9493","key":"460_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"1","key":"460_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijcard.2011.01.033","volume":"158","author":"M Briel","year":"2012","unstructured":"Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, et al. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012;158(1):93\u2013100.","journal-title":"Int J Cardiol"},{"issue":"22","key":"460_CR12","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"460_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.pharmthera.2014.02.007","volume":"143","author":"B Yeganeh","year":"2014","unstructured":"Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87\u2013110.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"460_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.leu.2402476","volume":"16","author":"WW Wong","year":"2002","unstructured":"Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508\u201319.","journal-title":"Leukemia"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fimmu.2013.00062","volume":"4","author":"C Pich","year":"2013","unstructured":"Pich C, Teiti I, Rochaix P, Mariame B, Couderc B, Favre G, et al. Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol. 2013;4:62.","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"460_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","volume":"10","author":"TR Pedersen","year":"2010","unstructured":"Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):10\u20137.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"460_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.atherosclerosis.2007.07.031","volume":"197","author":"K Mausner-Fainberg","year":"2008","unstructured":"Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2008;197(2):829\u201339.","journal-title":"Atherosclerosis"},{"issue":"15","key":"460_CR18","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","volume":"103","author":"I Jialal","year":"2001","unstructured":"Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103(15):1933\u20135.","journal-title":"Circulation"},{"issue":"1","key":"460_CR19","first-page":"10","volume":"9","author":"KK Chan","year":"2003","unstructured":"Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"460_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrclinonc.2013.169","volume":"10","author":"N Gronich","year":"2013","unstructured":"Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10(11):625\u201342.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"460_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3892\/ijo.2011.1273","volume":"40","author":"C Spampanato","year":"2012","unstructured":"Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935\u201341.","journal-title":"Int J Oncol"},{"issue":"26","key":"460_CR22","doi-asserted-by":"publisher","first-page":"15865","DOI":"10.1073\/pnas.2237238100","volume":"100","author":"J Ye","year":"2003","unstructured":"Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA. 2003;100(26):15865\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"460_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/hep.22916","volume":"50","author":"L Delang","year":"2009","unstructured":"Delang L, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology. 2009;50(1):6\u201316.","journal-title":"Hepatology"},{"issue":"6","key":"460_CR24","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.3892\/mmr.2016.5868","volume":"14","author":"W Li","year":"2016","unstructured":"Li W, Cao F, Li J, Wang Z, Ren Y, Liang Z, et al. Simvastatin exerts anti-hepatitis B virus activity by inhibiting expression of minichromosome maintenance protein 7 in HepG2.2.15 cells. Mol Med Rep. 2016;14(6):5334\u201342.","journal-title":"Mol Med Rep."},{"issue":"3","key":"460_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hep.23787","volume":"52","author":"SA Harrison","year":"2010","unstructured":"Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864\u201374.","journal-title":"Hepatology"},{"issue":"2","key":"460_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/jcm9020326","volume":"9","author":"GH Jeong","year":"2020","unstructured":"Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, et al. Statin and cancer mortality and survival: an umbrella systematic review and meta-analysis. J Clin Med. 2020;9(2):326.","journal-title":"J Clin Med."},{"issue":"6","key":"460_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/jcm8060819","volume":"8","author":"GH Jeong","year":"2019","unstructured":"Jeong GH, Lee KH, Kim JY, Eisenhut M, Kronbichler A, van der Vliet HJ, et al. Effect of statin on cancer incidence: an umbrella systematic review and meta-analysis. J Clin Med. 2019;8(6):819.","journal-title":"J Clin Med."},{"issue":"21","key":"460_CR28","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1056\/NEJMoa043792","volume":"352","author":"JN Poynter","year":"2005","unstructured":"Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"460_CR29","doi-asserted-by":"publisher","first-page":"e0250716","DOI":"10.1371\/journal.pone.0250716","volume":"16","author":"KT Han","year":"2021","unstructured":"Han KT, Kim S. Do cholesterol levels and continuity of statin use affect colorectal cancer incidence in older adults under 75 years of age? PLoS ONE. 2021;16(4):e0250716.","journal-title":"PLoS ONE"},{"issue":"6","key":"460_CR30","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/cam4.2151","volume":"8","author":"Y Li","year":"2019","unstructured":"Li Y, He X, Ding Y, Chen H, Sun L. Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta-analysis. Cancer Med. 2019;8(6):3305\u201313.","journal-title":"Cancer Med"},{"issue":"11","key":"460_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/jnci\/djr108","volume":"103","author":"WR Farwell","year":"2011","unstructured":"Farwell WR, D\u2019Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"460_CR32","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-19-2853","volume":"26","author":"EH Allott","year":"2020","unstructured":"Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin Cancer Res. 2020;26(5):1086\u201393.","journal-title":"Clin Cancer Res"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2018.11.033","volume":"112","author":"MI Van Rompay","year":"2019","unstructured":"Van Rompay MI, Solomon KR, Nickel JC, Ranganathan G, Kantoff PW, McKinlay JB. Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. Eur J Cancer. 2019;112:118\u201326.","journal-title":"Eur J Cancer"},{"issue":"4","key":"460_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/cam4.4514","volume":"11","author":"SI Seo","year":"2022","unstructured":"Seo SI, Park CH, Kim TJ, Bang CS, Kim JY, Lee KJ, et al. Aspirin, metformin, and statin use on the risk of gastric cancer: a nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer Med. 2022;11(4):1217\u201331.","journal-title":"Cancer Med"},{"key":"460_CR35","doi-asserted-by":"crossref","unstructured":"E JY, Lu SE, Lin Y, Graber JM, Rotter D, Zhang L, et al. Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1225\u201332.","DOI":"10.1158\/1055-9965.EPI-17-0227"},{"issue":"2","key":"460_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MPA.0000000000001226","volume":"48","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas. 2019;48(2):142\u201350.","journal-title":"Pancreas"},{"issue":"5","key":"460_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.canep.2014.06.009","volume":"38","author":"KA McGlynn","year":"2014","unstructured":"McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, et al. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38(5):523\u20137.","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"460_CR38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/ajg.2010.475","volume":"106","author":"HF Chiu","year":"2011","unstructured":"Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol. 2011;106(5):894\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"460_CR39","doi-asserted-by":"publisher","first-page":"djv009","DOI":"10.1093\/jnci\/djv009","volume":"107","author":"KA McGlynn","year":"2015","unstructured":"McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, et al. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst. 2015;107(4):djv009.","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"460_CR40","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/ijc.32426","volume":"146","author":"KT Tran","year":"2020","unstructured":"Tran KT, McMenamin UC, Coleman HG, Cardwell CR, Murchie P, Iversen L, et al. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer. 2020;146(5):1250\u201360.","journal-title":"Int J Cancer"},{"key":"460_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12885-016-2651-0","volume":"16","author":"UC Mc Menamin","year":"2016","unstructured":"Mc Menamin UC, Murray LJ, Hughes CM, Cardwell CR. Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer. 2016;16:600.","journal-title":"BMC Cancer"},{"issue":"7","key":"460_CR42","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ijc.33869","volume":"150","author":"DS Kim","year":"2022","unstructured":"Kim DS, Ahn HS, Kim HJ. Statin use and incidence and mortality of breast and gynecology cancer: a cohort study using the National Health Insurance claims database. Int J Cancer. 2022;150(7):1156\u201365.","journal-title":"Int J Cancer"},{"issue":"12","key":"460_CR43","doi-asserted-by":"publisher","first-page":"e0189233","DOI":"10.1371\/journal.pone.0189233","volume":"12","author":"A Couttenier","year":"2017","unstructured":"Couttenier A, Lacroix O, Vaes E, Cardwell CR, De Schutter H, Robert A. Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study. PLoS ONE. 2017;12(12):e0189233.","journal-title":"PLoS ONE"},{"key":"460_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejogrb.2021.11.013","volume":"268","author":"Y Chen","year":"2022","unstructured":"Chen Y, Han L, Zheng A. Association between statin use and the risk, prognosis of gynecologic cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;268:74\u201381.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"460_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1055-9965.EPI-05-0866","volume":"15","author":"J Fortuny","year":"2006","unstructured":"Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, et al. Statin use and risk of lymphoid neoplasms: results from the European Case\u2013Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev. 2006;15(5):921\u20135.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"460_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/hon.2265","volume":"35","author":"X Ye","year":"2017","unstructured":"Ye X, Mneina A, Johnston JB, Mahmud SM. Associations between statin use and non-Hodgkin lymphoma (NHL) risk and survival: a meta-analysis. Hematol Oncol. 2017;35(2):206\u201314.","journal-title":"Hematol Oncol"},{"key":"460_CR47","doi-asserted-by":"publisher","first-page":"26256","DOI":"10.1038\/srep26256","volume":"6","author":"GC Zhong","year":"2016","unstructured":"Zhong GC, Liu Y, Ye YY, Hao FB, Wang K, Gong JP. Meta-analysis of studies using statins as a reducer for primary liver cancer risk. Sci Rep. 2016;6:26256.","journal-title":"Sci Rep"},{"issue":"2","key":"460_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323\u201332.","journal-title":"Gastroenterology"},{"issue":"7","key":"460_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/MEG.0000000000000867","volume":"29","author":"YX Zheng","year":"2017","unstructured":"Zheng YX, Zhou PC, Zhou RR, Fan XG. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(7):759\u201366.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"460_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.2011.36.0917","volume":"30","author":"YT Tsan","year":"2012","unstructured":"Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623\u201330.","journal-title":"J Clin Oncol"},{"issue":"3","key":"460_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896\u2013907.","journal-title":"Hepatology"},{"issue":"6","key":"460_CR52","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.30973","volume":"71","author":"MJ Goh","year":"2020","unstructured":"Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, et al. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 2020;71(6):2023\u201332.","journal-title":"Hepatology"},{"key":"460_CR53","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/ijc.33441","volume":"148","author":"KR Getz","year":"2020","unstructured":"Getz KR, Bellile E, Zarins KR, Rullman C, Chinn SB, Taylor JMG, et al. Statin use and head and neck squamous cell carcinoma outcomes. Int J Cancer. 2020;148:2440.","journal-title":"Int J Cancer."},{"issue":"5","key":"460_CR54","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","volume":"63","author":"JC Hsiang","year":"2015","unstructured":"Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol. 2015;63(5):1190\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2015.07.009.","journal-title":"J Hepatol."},{"issue":"1","key":"460_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology. 2016;64(1):47\u201357. https:\/\/doi.org\/10.1002\/hep.28506.","journal-title":"Hepatology."},{"issue":"5","key":"460_CR56","doi-asserted-by":"publisher","first-page":"318","DOI":"10.7326\/M18-2753","volume":"171","author":"TG Simon","year":"2019","unstructured":"Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med. 2019;171(5):318\u201327. https:\/\/doi.org\/10.7326\/M18-2753.","journal-title":"Ann Intern Med."},{"issue":"12","key":"460_CR57","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","volume":"31","author":"YT Tsan","year":"2013","unstructured":"Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol. 2013;31(12):1514\u201321. https:\/\/doi.org\/10.1200\/JCO.2012.44.6831.","journal-title":"J Clin Oncol."},{"issue":"2","key":"460_CR58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-12-0290","volume":"20","author":"X Yang","year":"2013","unstructured":"Yang X, Wang Y, Luk AO, So WY, Ma RC, Kong AP, Xu G, Chan JC. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes. Endocr Relat Cancer. 2013;20(2):161\u201371. https:\/\/doi.org\/10.1530\/ERC-12-0290.","journal-title":"Endocr Relat Cancer."}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-022-00460-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-022-00460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T08:02:54Z","timestamp":1662278574000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-022-00460-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s13027-022-00460-0","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is not a study involving human participants or animals, thus ethics approval and consent to participate were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}